Matthew Volgraf, PhD

Matt Volgraf is a medicinal chemist with experience leading both chemistry and project teams toward the nomination of clinical candidates. In his current role, Matt is responsible for leading the internal chemistry operations at Septerna, including oversight of the internal chemistry labs and leading internal medicinal chemistry strategies enabling both platform and pipeline projects.

Prior to joining Septerna, Matt was a Principal Scientist in the Discovery Chemistry department at Genentech. Matt was involved in the nomination of two clinical candidates, including GDC-6599, a TRPA1 antagonist for the treatment of respiratory disease, which is currently in Phase 2 clinical trials.

Matt has authored and co-authored more than 25 publications and is a named inventor on more than 20 patents. He obtained his PhD from the University of California, Berkeley, and performed post-doctoral studies at Memorial Sloan Kettering Cancer Center.